Cumberland Pharmaceuticals plans NDA filing for ifetroban in DMD heart disease
The company said it will submit a New Drug Application after a fall pre-NDA meeting with the FDA, using Phase 2 and natural history data rather than a new Phase 3 trial.
On October 26, 2026, Cumberland Pharmaceuticals Inc. issued a press release providing an update on its ifetroban product candidate, in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy.1 The company said it plans to file a New Drug Application with the FDA for ifetroban for this indication, pursuing Traditional Approval following a pre-NDA meeting held this fall.1
The filing will draw on multiple data sources. The planned submission is expected to include results from the FIGHT DMD trial and its ongoing open-label extension, two natural history databases of DMD patients, preclinical findings previously published in the Journal of the American Heart Association, manufacturing details, and a safety database covering more than 1,400 subjects across roughly 30 clinical studies of ifetroban.1
In the 12-month Phase 2 FIGHT DMD study, high-dose ifetroban produced a statistically significant 5.4% absolute improvement in left ventricular ejection fraction compared with a combined placebo and natural-history control group (p=0.002).1 The high-dose group also showed lower levels of cardiac damage markers NT-proBNP and cardiac troponin I.1
The regulatory path included several FDA interactions. After an End-of-Phase 2 meeting in September 2025 and a follow-up Type C meeting in January 2026, the FDA suggested a Phase 3 randomized, placebo-controlled trial and raised questions about the LVEF endpoint, the comparator, and the statistical analysis plan.1 Cumberland is proposing to use the FIGHT DMD trial as the pivotal study alongside natural history comparisons, though the FDA raised concerns about whether this data package would meet the substantial evidence standard and requested further analysis.1 The FDA subsequently granted Cumberland's request for rolling review of the NDA.1
The company cautioned that there is no assurance the FDA will accept the NDA for filing or approve ifetroban based on the submitted data, even with the additional analyses requested.1 Ifetroban currently holds Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA for this indication.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.